Lincoln Pharmaceuticals Limited
NSE: LINCOLN
NSE
532.55
0.60 (0.11%)
Prev Close
531.95
Open Price
531
Volume
8,725
Today Low / High
531 / 536
52 WK Low / High
499 / 979.5
Range
506 - 559
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 532.55, with a change of 0.6 (0.11279%). The expected target range on the NSE is between 506 - 559. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
03 Oct
531.00
0.29%
01 Oct
531.00
0.18%
30 Sep
535.00
-0.52%
29 Sep
537.00
-0.98%
26 Sep
541.00
-0.68%
25 Sep
546.20
-0.42%
24 Sep
548.00
-0.44%
23 Sep
552.00
-0.72%
22 Sep
555.00
-0.82%
19 Sep
554.00
0.18%
18 Sep
557.90
-0.82%
17 Sep
555.90
-0.06%
16 Sep
553.50
0.03%
15 Sep
554.35
-0.15%
12 Sep
558.65
-0.77%
11 Sep
558.15
0.10%
10 Sep
551.50
1.02%
09 Sep
559.95
-1.46%
08 Sep
552.00
1.48%
Lincoln Pharmaceuticals Limited Graph
Lincoln Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lincoln Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 532.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 532.55 | 537.88 | 484.09 - 591.66 |
| 543.20 | 434.56 - 651.84 | ||
| 548.53 | 383.97 - 713.08 | ||
| Bearish Scenario | 532.55 | 527.22 | 474.50 - 579.95 |
| 521.90 | 417.52 - 626.28 | ||
| 516.57 | 361.60 - 671.55 |
Overview of Lincoln Pharmaceuticals Limited
ISIN
INE405C01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
119,498
Market Cap
10,666,831,646
Last Dividend
1.8
Official Website
IPO Date
2015-12-17
DCF Diff
-551.71
DCF
1,101
Financial Ratios Every Investor Needs
Stock Dividend of LINCOLN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-12 | September 12, 25 | 1.8 | 1.8 | 2025-09-12 | 2025-10-30 | |
| 2024-09-13 | September 13, 24 | 1.8 | 1.8 | 2024-09-13 | 2024-10-30 | |
| 2023-09-15 | September 15, 23 | 1.5 | 1.5 | 2023-09-15 | 2023-10-30 | |
| 2022-09-15 | September 15, 22 | 1.5 | 1.5 | 2022-09-16 | 2022-10-30 | |
| 2021-09-16 | September 16, 21 | 1.5 | 1.5 | 2021-09-17 | 2021-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 623.23 Cr | 291.32 Cr | 331.91 Cr | 0.5326 | 10.60 Cr | 113.05 Cr | 88.59 Cr | 82.35 Cr | 41.11 | 123.97 Cr | 0.1321 |
| 2024-03-31 | 580.55 Cr | 283.08 Cr | 297.47 Cr | 0.5124 | 0.00 Cr | 103.14 Cr | 83.22 Cr | 93.30 Cr | 46.58 | 134.33 Cr | 0.1607 |
| 2023-03-31 | 504.95 Cr | 245.75 Cr | 259.21 Cr | 0.5133 | 0.00 Cr | 19.91 Cr | 77.99 Cr | 72.90 Cr | 36.40 | 111.68 Cr | 0.1444 |
| 2022-03-31 | 468.20 Cr | 221.93 Cr | 246.27 Cr | 0.5260 | 0.00 Cr | 18.63 Cr | 164.99 Cr | 69.36 Cr | 34.63 | 105.48 Cr | 0.1481 |
| 2021-03-31 | 414.75 Cr | 201.42 Cr | 213.33 Cr | 0.5144 | 9.36 Cr | 14.52 Cr | 72.02 Cr | 62.25 Cr | 31.08 | 92.84 Cr | 0.1501 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 13.41 Cr | 797.01 Cr | 125.34 Cr | 671.6686 Cr | 0.00 Cr | -13.41 Cr | 78.68 Cr | 186.00 Cr | 0.00 Cr | 0.00 Cr | 107.06 Cr | 106.2158 Cr |
| 2024-03-31 | 5.75 Cr | 700.29 Cr | 107.45 Cr | 592.8359 Cr | 1.07 Cr | -4.68 Cr | 77.17 Cr | 182.48 Cr | 1.32 Cr | 0.00 Cr | 75.15 Cr | 92.2771 Cr |
| 2023-03-31 | 5.05 Cr | 587.42 Cr | 84.95 Cr | 502.4744 Cr | 2.00 Cr | -3.05 Cr | 70.03 Cr | 158.48 Cr | 0.82 Cr | 4.72 Cr | 60.61 Cr | 72.1452 Cr |
| 2022-03-31 | 6.93 Cr | 534.36 Cr | 101.48 Cr | 432.8774 Cr | 2.04 Cr | -4.89 Cr | 72.74 Cr | 150.63 Cr | 0.12 Cr | 4.54 Cr | 29.41 Cr | 90.4862 Cr |
| 2021-03-31 | 11.44 Cr | 452.36 Cr | 85.97 Cr | 366.3923 Cr | 0.52 Cr | -10.92 Cr | 46.61 Cr | 114.49 Cr | 3.54 Cr | 4.29 Cr | 26.32 Cr | 75.8403 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 93.0155 Cr | -78.9474 Cr | -6.4015 Cr | 73.7713 Cr | 7.6666 Cr | 13.4138 Cr | -19.0292 Cr | 109.1886 Cr | -0.9973 Cr | -3.6054 Cr | -1.5092 Cr |
| 2024-03-31 | 63.2172 Cr | -57.3416 Cr | -5.1804 Cr | 23.7407 Cr | 0.6952 Cr | 5.7472 Cr | -39.4759 Cr | 93.3049 Cr | -0.9019 Cr | -3.0045 Cr | -7.1402 Cr |
| 2023-03-31 | 39.2619 Cr | -36.6428 Cr | -4.5013 Cr | 24.9799 Cr | -1.8820 Cr | 5.0520 Cr | -14.2588 Cr | 100.4798 Cr | -0.1444 Cr | -3.0045 Cr | 2.7141 Cr |
| 2022-03-31 | 76.1319 Cr | -78.0802 Cr | -2.5561 Cr | 30.6067 Cr | -4.5044 Cr | 6.9340 Cr | -45.5252 Cr | 95.9393 Cr | 1.4803 Cr | -3.0000 Cr | -26.1292 Cr |
| 2021-03-31 | 69.2695 Cr | -64.2273 Cr | -5.7453 Cr | 60.5192 Cr | -0.7031 Cr | 11.4384 Cr | -8.7503 Cr | 83.7205 Cr | -4.5543 Cr | 0.0000 Cr | 0.7835 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 154.07 Cr | 69.38 Cr | 84.68 Cr | 0.5496 | 20.33 Cr | 27.68 Cr | 13.82 | 39.08 Cr | 0.1796 |
| 2025-03-31 | 168.18 Cr | 80.15 Cr | 88.03 Cr | 0.5234 | 23.49 Cr | 11.58 Cr | 5.78 | 19.84 Cr | 0.0688 |
| 2024-12-31 | 146.55 Cr | 68.64 Cr | 77.92 Cr | 0.5317 | 20.44 Cr | 20.77 Cr | 10.37 | 32.63 Cr | 0.1417 |
| 2024-09-30 | 161.21 Cr | 72.29 Cr | 88.92 Cr | 0.5516 | 25.15 Cr | 26.33 Cr | 13.15 | 38.36 Cr | 0.1633 |
| 2024-06-30 | 147.28 Cr | 70.24 Cr | 77.04 Cr | 0.5231 | 19.51 Cr | 23.67 Cr | 11.82 | 33.14 Cr | 0.1607 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 196.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -671.67 Cr |
| 2025-03-31 | 13.41 Cr | 182.58 Cr | 195.71 Cr | 201.69 Cr | 78.68 Cr | 499.94 Cr | 186.00 Cr | 797.01 Cr | 125.34 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 197.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -639.26 Cr |
| 2024-09-30 | 32.91 Cr | 164.50 Cr | 197.41 Cr | 224.64 Cr | 84.77 Cr | 523.13 Cr | 183.39 Cr | 779.79 Cr | 140.53 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 152.75 Cr | 0.00 Cr | 0.00 Cr | 152.75 Cr | 0.00 Cr | 0.00 Cr | -592.84 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 27.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 11.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 20.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 26.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 23.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,631.20 | ₹3,913,789,293,226.00 | ₹4,041,732.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,866.00 | ₹1,557,243,570,792.00 | ₹654,877.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,514.70 | ₹1,189,532,641,500.00 | ₹382,145.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,248.10 | ₹1,038,883,805,225.00 | ₹2,742,529.00 |
| Mankind Pharma Limited | MANKIND | ₹2,448.00 | ₹1,010,432,783,520.00 | ₹606,798.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.30 | ₹994,456,675,136.00 | ₹577,179.00 |
| Lupin Limited | LUPIN | ₹1,973.60 | ₹901,457,328,285.00 | ₹763,761.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,442.00 | ₹650,672,730,000.00 | ₹110,809.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,093.30 | ₹634,990,414,426.00 | ₹517,527.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,980.20 | ₹558,814,041,982.00 | ₹419,674.00 |
| Laurus Labs Limited | LAURUSLABS | ₹864.40 | ₹466,624,642,696.00 | ₹1,995,641.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹875.70 | ₹335,014,044,498.00 | ₹222,399.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,313.10 | ₹333,139,008,656.00 | ₹124,762.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,401.80 | ₹300,070,381,723.00 | ₹84,998.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,668.40 | ₹261,265,165,148.00 | ₹110,078.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,460.00 | ₹237,227,809,460.00 | ₹571,463.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,331.00 | ₹233,275,000,000.00 | ₹12,069.00 |
| Eris Lifesciences Limited | ERIS | ₹1,593.30 | ₹217,029,055,588.00 | ₹170,370.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,210.00 | ₹195,142,611,690.00 | ₹51,590.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹910.40 | ₹178,951,068,090.00 | ₹46,154.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,119.40 | ₹177,481,747,610.00 | ₹112,177.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,019.90 | ₹153,536,024,750.00 | ₹70,816.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹822.55 | ₹147,326,823,569.00 | ₹330,964.00 |
| Granules India Limited | GRANULES | ₹557.30 | ₹135,225,342,927.00 | ₹2,386,973.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,271.50 | ₹104,103,024,213.00 | ₹4,753.00 |
| Strides Pharma Science Limited | STAR | ₹832.35 | ₹76,719,958,498.00 | ₹180,349.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹384.95 | ₹75,289,220,069.00 | ₹234,116.00 |
| FDC Limited | FDC | ₹461.35 | ₹75,112,432,253.00 | ₹49,231.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹826.90 | ₹74,944,402,066.00 | ₹244,426.00 |
| Sequent Scientific Limited | SEQUENT | ₹201.84 | ₹50,442,409,442.00 | ₹1,023,854.00 |
| Innova Captab Limited | INNOVACAP | ₹850.00 | ₹48,641,189,650.00 | ₹92,638.00 |
| Suven Life Sciences Limited | SUVEN | ₹208.63 | ₹45,489,830,615.00 | ₹189,562.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹491.60 | ₹44,868,332,000.00 | ₹62,277.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.11 | ₹42,872,546,991.00 | ₹120,949.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹744.00 | ₹37,735,014,120.00 | ₹55,425.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,269.70 | ₹37,538,602,346.00 | ₹3,275.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹358.50 | ₹35,951,278,401.00 | ₹23,461.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹492.25 | ₹34,657,230,438.00 | ₹12,253.00 |
| Hikal Limited | HIKAL | ₹254.05 | ₹31,324,555,538.00 | ₹219,004.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹105.66 | ₹31,014,116,707.00 | ₹1,948,175.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.23 | ₹26,975,760,602.00 | ₹2,316,811.00 |
| Indoco Remedies Limited | INDOCO | ₹290.60 | ₹26,782,104,293.00 | ₹20,201.00 |
| Alembic Limited | ALEMBICLTD | ₹103.37 | ₹26,543,537,560.00 | ₹156,367.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹616.10 | ₹26,349,333,995.00 | ₹136,290.00 |
Key Executives
MD & Whole Time Director
Mr. Mahendrabhai Gulabdas Patel B.A, LLB
Gender: male
Year Born: 1954
Vice President of Technical
Mr. Laxmikant Harsola
Gender: male
Year Born:
Group Marketing Manager
Mr. Amit Dwivedi B-PHARM, MBA
Gender: male
Year Born: 1976
Whole Time Director
Mr. Ashish Rajnikant Patel
Gender: male
Year Born: 1981
Whole Time Director
Mr. Hashmukhbhai Ishwarlal Patel B.sc.
Gender: male
Year Born: 1958
Company Secretary & Compliance Officer
Ms. Trusha K. Shah
Gender: female
Year Born:
Whole Time Director
Mr. Munjal Mahendrabhai Patel
Gender: male
Year Born: 1982
Senior Manager of Planning & Administration
Mr. Sanjiv Patel
Gender: male
Year Born:
Chief Financial Officer
Mr. Darshit Ashvinkumar Shah
Gender: male
Year Born:
Senior Manager of Operation
Mr. Sanjay Bhatt
Gender: male
Year Born:
FAQs about Lincoln Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mahendrabhai Gulabdas Patel B.A, LLB.
What is the current market price of the stock?
The current price is ₹532.55.
What is the 52-week price range?
The range is ₹499-979.5.
What is the market capitalization of the company?
The market capitalization is ₹1,066.68 crores.
What is the dividend yield?
The dividend yield is 0.34%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 12.35.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lincoln Pharmaceuticals Limited (ISIN: INE405C01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,066.68 crores and an average daily volume of 119,498 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.8.